JSKN027 / Alphamab - LARVOL DELTA

IND application for JSKN027 was officially accepted by the CDE (HKEXnews) - "The Company plans to initiate a phase I clinical study of JSKN027 for the treatment of advanced malignant solid tumors, aiming to evaluate its safety, tolerability,pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity in such patient population and to determine the maximum tolerated dose and/or recommended Phase II dose."

New P1 trial • Solid Tumor